Why the study?
Genetic variations of AGT and AGTR1 may increase susceptibility to elevated blood pressure and hypertension.
Do AGT rs699 and AGTR1 rs5186 genetic polymorphisms increase susceptibility to elevated blood pressure and hypertension over 5 years?
Do AGT rs699 and AGTR1 rs5186 genetic polymorphisms increase susceptibility to elevated blood pressure and hypertension over 5 years?
Polymorphisms in the renin-angiotensin system genes AGT and AGTR1 are associated with increased risk of developing hypertension and metabolic syndrome.
Risk alleles linked to higher hypertension odds at 5 years; hypothesis-generating for genetic stratification, needs prospective validation before clinical use.
Purpose: The renin–angiotensin system plays an important role in the central regulation of blood pressure (BP). Genetic variations of angiotensinogen (AGT) and angiotensin II type 1 receptor (AGTR1) may increase susceptibility to elevated BP and hypertension. This study investigated the effects of AGT rs699 and AGTR1 rs5186 single nucleotide polymorphisms (SNPs) on BP at baseline and at a 5-year follow-up. Paticipants and Methods: The study population consisted of participants from the Electricity Generating Authority of Thailand cohort study (n=354); data were collected at baseline (2013) and 5 years later (2018). Genotyping of the two SNPs was performed using TaqMan ® assay and statistical analyses were performed with SNPStats software. Results: The frequencies of the two SNPs were within the Hardy–Weinberg equilibrium (p=0.22 for AGT rs699 and p=0.06 for AGTR1 rs5186). For each SNP, mutant genotypes were significantly associated with increased systolic BP and/or diastolic BP in the codominant and recessive models. Risk alleles of AGT rs699 and AGTR1 rs5186 were associated with increased odds of hypertension and hypertension with metabolic syndrome at follow-up. Conclusion: Overall, our results suggest that polymorphisms of genes in the renin–angiotensin system increase susceptibility to the development and progression of hypertension and the development of the metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Chaimati et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: